Search Within

Michael Scordo

Formats
  1. Meeting Abstract (250)
  2. Journal Article (104)
  3. Research Letter (15)
  4. Correspondence (7)
  5. Editorial (5)
  6. Review (4)
  7. Book Section (1)
  8. Guidelines (1)
Groups
  1. Bone Marrow Transplant (387)
  2. CTCR Scholars (387)
  3. Center for Hematologic Malignancies (387)
  4. Department of Medicine (387)
  5. Hematologic Malignancies, Division of (387)
  6. Survivorship Research (338)

More Groups

People
  1. Gunjan Shah (298)
  2. Sergio Giralt (278)
  3. Miguel-Angel Perales (177)
  4. Sean Devlin (152)
  5. Heather Landau (141)
  6. Parastoo Dahi (140)

More People

Years
  1. 2025 (22)
  2. 2024 (72)
  3. 2023 (81)
  4. 2022 (49)
  5. 2021 (27)
  6. 2020 (53)

More Years

Publications
  1. Blood (123)
  2. Biology of Blood and Marrow Transplantation (56)
  3. Clinical Lymphoma, Myeloma and Leukemia (36)
  4. Bone Marrow Transplantation (26)
  5. Blood Advances (21)
  6. Transplantation and Cellular Therapy (15)

More Publications

Publishers
  1. American Society of Hematology (144)
  2. Elsevier Inc. (122)
  3. Nature Publishing Group (40)
  4. American Society of Clinical Oncology (14)
  5. Wiley Blackwell (9)
  6. Oxford University Press (7)

More Publishers

Results (387)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Population pharmacokinetics of melphalan in a large cohort of autologous and allogeneic hematopoietic cell transplantation recipients: Towards individualized dosing regimens
    Journal Article

    Shah, G. L.; Boelens, J. J.; Carlow, D.; Lin, A.; Schofield, R.; Cruz Sitner, N.; Alperovich, A.; Ruiz, J.; Proli, A.; Dahi, P.; more...
    Clinical Pharmacokinetics (2022)

    Fulltext@MSK | Save
  • The Simplified Comorbidity Index: A new tool for prediction of nonrelapse mortality in allo-HCT
    Journal Article

    Shouval, R.; Fein, J. A.; Cho, C.; Avecilla, S. T.; Ruiz, J.; Alarcon Tomas, A.; Sanchez-Escamilla, M.; Castillo Flores, N.; Yáñez, L.; Barker, J. N.; more...
    Blood Advances (2022)

    Fulltext@MSK | Save
  • Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy
    Journal Article

    Shouval, R.; Alarcon Tomas, A.; Fein, J. A.; Flynn, J. R.; Markovits, E.; Mayer, S.; Afuye, A. O.; Alperovich, A.; Anagnostou, T.; Besser, M. J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Antithymocyte globulin exposure in CD34(+) T-cell–depleted allogeneic hematopoietic cell transplantation
    Journal Article

    Lakkaraja, M.; Scordo, M.; Mauguen, A.; Cho, C.; Devlin, S.; Ruiz, J. D.; Klein, E.; Avecilla, S. T.; Boulad, F.; Cancio, M. I.; more...
    Blood Advances (2022)

    Fulltext@MSK | Save
  • Novel agents may be preferable to chemotherapy for large B-cell lymphoma progressing after CD19-CAR-T: A multicenter observational study
    Meeting Abstract

    Tomas, A. A.; Fein, J. A.; Fried, S.; Fingrut, W.; Anagnostou, T.; Alperovich, A.; Shah, N.; Fraint, E.; Lin, R. J.; Scordo, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Five-year experience using bridging radiotherapy prior to chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies at Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Silverman, E. A.; Hubbeling, H.; Palomba, M. L.; Wijetunga, N. A.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide maintenance therapy for multiple myeloma: A randomized pilot study comparing patient-reported health related quality of life measures
    Meeting Abstract

    Shah, U. A.; Malik, M.; Werner, K.; Burge, M.; Devlin, S. M.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Tan, C.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)
    Meeting Abstract

    Maura, F.; Boyle, E. M.; Diamond, B.; Blaney, P.; Ghamlouch, H.; Ziccheddu, B.; Wang, Y.; Maclachlan, K. H.; Hoffman, J. E.; Hassoun, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Lesion characteristics and patterns of failure in diffuse large B cell lymphoma patients treated with bridging radiotherapy prior to chimeric antigen receptor T cell therapy
    Meeting Abstract

    Hubbeling, H.; Silverman, E. A.; Wijetunga, N. A.; Palomba, M. L.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save